Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (DE:29A)
FRANKFURT:29A
RESEARCH TOOLSreports
Amphastar Pharmaceuticals (29A) Stock Price & Analysis
0 Followers
29A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€32.00 - €59.00
Previous Close€37.64
Volume0.00
Average Volume (3M)56.00
Market Cap
€1.88B
Enterprise Value€2.22B
Total Cash (Recent Filing)$256.81M
Total Debt (Recent Filing)$623.64M
Price to Earnings (P/E)N/A
Beta0.22
Next Earnings
May 09, 2024EPS Estimate
€0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,095,862
10 Day Avg. Volume0
30 Day Avg. Volume56
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)75.68
Price to Sales (P/S)2.81
Price to Cash Flow (P/CF)20.70
P/FCF Ratio21.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.88
Enterprise Value/Gross Profit6.32
Enterprise Value/Ebitda8.86
Forecast
1Y Price Target
€61.43Price Target Upside63.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Amphastar Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAmphastar Pharmaceuticals reported higher-than-expected revenue and adjusted EPS, with key products like BAQSIMI, Primatene Mist, and epinephrine exceeding sales estimates.
Market LeadershipBAQSIMI, the only non-injectable product in the branded glucagon market, is patent protected until 2036, offering ease of use and a unique position among competitors.
Product PipelineAmphastar's pipeline includes difficult-to-develop complex generics with multiple launches anticipated in the near future.
Bears Say
Drug DevelopmentAMP-015 was slightly delayed due to an inspection.
EarningsEPS came in slightly below, driven largely by a miss on GM.
Product SalesLower than expected Baqsimi sales negatively impacted gross margins.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.25% Other Institutional Investors
98.75% Public Companies and
Individual Investors
29A FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was €32.00 and its highest was €59.00 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Currently, no data Available
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 10 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on Feb 28, 2024. The company reported €0.822 earnings per share for the quarter, missing the consensus estimate of €0.85 by -€0.028.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals does not currently pay dividends.
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is €0.73.
How many shares outstanding does Amphastar Pharmaceuticals have?
Currently, no data Available
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of €0.822 in its last earnings report, missing expectations of €0.85. Following the earnings report the stock price went down -10.588%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Among the largest hedge funds holding Amphastar Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Amphastar Pharmaceuticals’s shares valued at 701K.
---
Amphastar Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€61.43 (63.21% Upside)
€61.43 (63.21% Upside)
Blogger Sentiment
Bullish
DE:29A Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $589.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.73%
12-Months-Change
Fundamentals
Return on Equity
23.55%
Trailing 12-Months
Asset Growth
103.90%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
---
29A Company Deck
---
29A Earnings Call
Q4 2024
0:00 / 0:00
---
29A Stock 12 Months Forecast
Average Price Target
€61.43
▲(63.21% Upside)
Technical Analysis
Best Analysts Covering 29A
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+28.76%
reiterated a buy rating 12 days ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +28.76% per trade.
---